切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2023, Vol. 12 ›› Issue (03) : 127 -133. doi: 10.3877/cma.j.issn.2095-3216.2023.03.002

论著

肠源性腹膜透析相关性腹膜炎治疗失败的危险因素：多中心回顾性研究
于梦园, 杨立明, 朱学研, 张晓暄, 刘声茂, 谢舜昀, 倪册, 庄小花, 崔文鹏†()   
  1. 130041　长春，吉林大学第二医院肾病内科
    130031　长春，吉林大学第一医院二部肾病内科
    132011　长春，吉林市中心医院肾病内科
    130011　长春，吉林省一汽总医院肾病内科
  • 收稿日期:2023-04-11 出版日期:2023-06-28
  • 通信作者: 崔文鹏
  • 基金资助:
    吉林省卫生厅项目(2018FP031)

Risk factors for treatment failure of enterogenous PDAP, a multicenter retrospective study

Mengyuan Yu, Liming Yang, Xueyan Zhu, Xiaoxuan Zhang, Shengmao Liu, Shunyun Xie, Ce Ni, Xiaohua Zhuang, Wenpeng Cui†()   

  1. Department of Nephrology, Second Hospital of Jilin University, Changchun 130041
    Department of Nephrology, Second Division of First Hospital of Jilin University, Changchun 130031
    Department of Nephrology, Jilin Central Hospital, Changchun 132011
    Department of Nephrology, Jilin FAW General Hospital, Changchun 130011; Jilin Province, China
  • Received:2023-04-11 Published:2023-06-28
  • Corresponding author: Wenpeng Cui
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

于梦园, 杨立明, 朱学研, 张晓暄, 刘声茂, 谢舜昀, 倪册, 庄小花, 崔文鹏. 肠源性腹膜透析相关性腹膜炎治疗失败的危险因素：多中心回顾性研究[J/OL]. 中华肾病研究电子杂志, 2023, 12(03): 127-133.

Mengyuan Yu, Liming Yang, Xueyan Zhu, Xiaoxuan Zhang, Shengmao Liu, Shunyun Xie, Ce Ni, Xiaohua Zhuang, Wenpeng Cui. Risk factors for treatment failure of enterogenous PDAP, a multicenter retrospective study[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(03): 127-133.

目的

探讨肠源性腹膜透析相关性腹膜炎(PDAP)治疗失败的危险因素。

方法

回顾性收集2013年至2019年吉林省4家三甲医院PDAP患者临床资料，按照PDAP的致病菌类型，将研究对象分为肠源性PDAP组(284例)和非肠源性PDAP组(519例)。采用广义估计方程(GEE)比较两组患者的临床资料、初始疗效、当次PDAP治疗结果以及肠源性PDAP治疗失败的危险因素。

结果

本研究共纳入803例次PDAP，其中肠源性PDAP组为284例次，大肠埃希菌最多，为100例次(35.21%)。与非肠源性PDAP组相比，肠源性PDAP组的女性占比较高(55.99%和47.21%，P＝0.043),且原发病为糖尿病肾病的比例较高(16.96%和11.27%, P＝0.029)。两组患者在年龄、血红蛋白、血清白蛋白水平等方面均未见明显差异(均P>0.05)。与非肠源性PDAP组相比，肠源性PDAP组初始疗效和当次治疗结果均较差(均P<0.001)。多因素GEE分析显示，长透析龄、生活在农村、低血清白蛋白，以及肺炎克雷伯杆菌、铜绿假单胞菌、真菌及混合菌感染均为肠源性PDAP治疗失败的独立危险因素(P<0.05)。

结论

肠源性PDAP的治疗效果比非肠源性PDAP差。长透析龄、农村生活、低血清白蛋白水平及肺炎克雷伯杆菌、铜绿假单胞菌、真菌及混合菌感染是肠源性PDAP治疗失败的独立危险因素。

关键词: 腹膜透析, 腹膜透析相关性腹膜炎, 肠源菌, 危险因素
Objective

To investigate the risk factors for treatment failure of enterogenous peritoneal dialysis-associated peritonitis (PDAP).

Methods

Retrospective collection of clinical data on PDAP patients from four hospitals in Jilin Province from 2013 to 2019. According to the type of pathogenic bacteria from PDAP, the study subjects were divided into the enterogenous PDAP group (284 cases) and the non-enterogenous PDAP group (519 cases). The generalized estimation equation (GEE) was used to compare the two groups in clinical data, initial therapeutic effect, and current therapeutic effect of PDAP, as well as risk factors for treatment failure of enterogenous PDAP.

Results

This study included a total of 803 cases of PDAP, including 284 cases in the enterogenous PDAP group, with E. coli being of the highest number of 100 cases and accounting for 35.21% of the enterogenous PDAP group. Compared with the non-enterogenous PDAP group, the enterogenous PDAP group showed higher proportion of female patients (55.99% versus 47.21%, P=0.043), and higher proportion of diabetic nephropathy as primary disease (16.96% versus 11.27%, P=0.029). There was no significant difference between the two groups in age, hemoglobin level, and serum albumin level (all P>0.05). Compared with the non-enterogenous PDAP group, the enterogenous PDAP group showed worse initial therapeutic effect and current therapeutic effect of PDAP (both P<0.001). Multivariate GEE analysis showed that long dialysis age, living in rural areas, low serum albumin, Klebsiella pneumoniae, Pseudomonas aeruginosa, fungi, and mixed bacteria were independent risk factors for the treatment failure of enterogenous PDAP (P<0.05).

Conclusion

The therapeutic effect of the enterogenous PDAP was worse than that of the non-enterogenous PDAP. The independent risk factors for treatment failure of the enterogenous PDAP included long dialysis age, living in rural areas, low serum albumin levels, and related types of enterogenous microorganisms.

Key words: Peritoneal dialysis, Peritoneal dialysis-associated peritonitis, Enterogenous microorganisms, Risk factors
图1 筛选病例流程图注：PDAP：腹膜透析相关性腹膜炎。
表1 两组患者的临床资料对比
临床资料 总体(n＝803) 肠源性PDAP组(n＝284) 非肠源性PDAP组(n＝519) Wald χ2值 P值
年龄(岁) 56.88(47，68) 57.79(48，69) 56.39(46，68) 1.239 0.266
女性[例(%)] 404(50.31) 159(55.99) 245(47.21) 4.099 0.043
当次PDAP透析龄(月) 23.45(7，33) 25.05(7，39.75) 22.57(7，31) 1.911 0.167
农村生活 249(31.01) 78(27.46) 171(32.95) 2.069 0.150
之前是否应用抗生素[例(%)] 80(9.96) 32(11.27) 48(9.25) 0.766 0.382
当次PDAP实验室指标          
血白细胞(109/L) 9.63(6.40，11.54) 9.60(6.32，11.92) 9.65(6.40，11.40) 0.018 0.893
血红蛋白(g/L) 99.43(85，113) 100.52(86，114.75) 98.83±20.04 1.152 0.283
血白蛋白(g/L) 28.81(24.70，33.19) 28.67±6.23 28.89(25，33.20) 0.183 0.669
血清钾(mmol/L) 3.83(3.29，4.26) 3.89(3.33，4.37) 3.79(3.29，4.22) 2.282 0.131
估算的肾小球滤过率[ml/(min·1.73 m2)] 6.46(4.44，7.65) 6.33(4.28，7.66) 6.52(4.48，7.62) 0.569 0.451
原发病[例(%)]          
肾小球肾炎 362(45.08) 136(47.89) 226(43.55) 1.003 0.316
糖尿病肾病 205(25.53) 73(25.70) 132(25.43) 0.005 0.941
高血压肾病 120(14.94) 32(11.27) 88(16.96) 4.742 0.029
多囊肾病 42(5.23) 17(5.99) 25(4.82) 0.262 0.609
间质性肾病 32(3.99) 16(5.63) 16(3.08) 3.377 0.066
其他原发病 42(5.23) 10(3.52) 32(6.17) 1.708 0.191
疾病情况[例(%)]          
合并糖尿病 282(35.12) 95(33.45) 187(36.03) 0.409 0.523
合并高血压 698(86.92) 244(85.92) 454(87.48) 0.282 0.596
合并腹泻或便秘 246(30.64) 94(33.10) 152(29.29) 1.124 0.289
当次PDAP性质[例(%)]          
首发 465(57.91) 162(57.04) 303(58.38) 0.116 0.734
复发 47(5.85) 19(6.69) 28(5.39) 0.390 0.532
再发 46(5.73) 17(5.99) 29(5.59) 0.053 0.818
重现 42(5.23) 13(4.58) 29(5.59) 0.330 0.565
其他 203(25.28) 73(25.70) 130(25.05) 0.037 0.847
表2 肠源性PDAP组致病菌构成
病原菌 株数(株) 构成比(%)
革兰氏阴性菌 187 65.85
大肠埃希菌 100 35.21
肺炎克雷伯杆菌 21 7.40
肠杆菌 30 10.56
铜绿假单胞菌 13 4.58
其他 23 8.10
革兰氏阳性菌 19 6.69
肠球菌 19 6.69
真菌 28 9.86
厌氧菌 1 0.35
混合菌 49 17.25
表3 非肠源性PDAP组致病菌构成
病原菌 株数(株) 构成比(%)
革兰氏阳性菌    
凝固酶阴性葡萄球菌 232 44.70
金黄色葡萄球菌 48 9.25
链球菌 92 17.72
其他 33 6.36
革兰氏阴性菌    
不动杆菌 25 4.82
假单胞菌 11 2.12
其他 24 4.62
真菌 14 2.70
抗酸杆菌 10 1.93
混合菌 30 5.78
表4 两组患者的治疗结果对比
组别 初始治疗评价[例(%)] 后续治疗评价[例(%)]
有效 无效 完全治愈 复发 拔管 PDAP相关性死亡
肠源性PDAP组 185(65.14) 99(34.86) 174(61.27) 30(10.56) 58(20.42) 22(7.75)
非肠源性PDAP组 437(84.20) 82(15.80) 433(83.43) 37(7.13) 30(5.78) 19(3.66)
Wald χ2值 30.912 42.920
P值 <0.001 <0.001
表5 肠源性PDAP组发生腹膜透析相关性腹膜炎治疗失败的危险因素
变量 单因素 多因素
OR值 95%CI P值 B值 OR值 95%CI P值 B值 Wald χ2值
年龄 1.004 0.987~1.021 0.645 0.004          
男性 0.740 0.435~1.260 0.268 －0.301          
当次PDAP透析龄(月) 1.025 1.015~1.036 <0.001 0.025 1.037 1.021~1.052 <0.001 0.036 21.795
入院前使用抗生素 2.938 1.424~6.060 0.004 1.078 0.998 0.390~2.554 0.997 －0.002 <0.001
农村生活 1.799 1.029~3.144 0.039 0.587 2.087 1.056~4.122 0.034 0.736 4.485
当次PDAP实验室指标                  
血清白蛋白(g/L) 0.965 0.919~1.013 0.150 －0.036 0.930 0.869~0.996 0.038 －0.072 4.296
血红蛋白(g/L) 1.002 0.989~1.016 0.716 0.002          
血尿素氮 0.954 0.915~0.995 0.029 －0.047 0.949 0.900~1.001 0.055 －0.052 3.671
病原菌类型                  
G－菌                  
大肠埃希菌 参考                
肺炎克雷伯杆菌 2.457 0.854~7.072 0.096 0.899 3.831 1.242~11.816 0.019 1.343 5.464
肠杆菌 0.683 0.174~2.683 0.585 －0.382 1.014 0.234~4.397 0.985 0.014 <0.001
铜绿假单胞菌 5.265 1.441~19.240 0.012 1.661 9.631 1.667~55.630 0.011 2.265 6.408
其他G－菌 0.921 0.239~3.552 0.905 －0.082 1.952 0.494~7.710 0.340 0.669 0.912
真菌 51.190 10.921~239.945 <0.001 3.936 99.607 16.280~609.447 <0.001 4.601 24.789
混合菌 5.005 2.249~11.140 <0.001 1.610 9.677 3.692~25.365 <0.001 2.270 21.314
G+菌                  
肠球菌 0.341 0.041~2.827 0.319 －1.075 0.576 0.059~5.599 0.634 －0.552 0.227
[8]
官继超，龚淑文，汪艳艳，等. 肠源性腹膜透析相关性腹膜炎临床特点及危险因素分析[J]. 中国全科医学，2016(15): 1781-1785.
[9]
Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment [J]. Perit Dial Int, 2022, 42(2): 110-153.
[10]
中国腹膜透析相关感染防治专家组. 腹膜透析相关感染的防治指南[J]. 中华肾脏病杂志，2018(2): 139-148.
[11]
Buchanan RE, Gibbons NE. Bergey′s manual of determinative bacteriology [M]. 8th edition. Baltimore: Williams & Wilkins, 1984: 382-473.
[12]
Jorgensen JH, Pfaller MA. Manual of clinical microbiology [M]. 8th edition. Washington DC: Am Soc Microbiol, 2017: 497-519.
[13]
Yip T, Tse KC, Ng F, et al. Clinical course and outcomes of single-organism Enterococcus peritonitis in peritoneal dialysis patients [J]. Perit Dial Int, 2011, 31(5): 522-528.
[14]
Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the human microbiome project healthy cohort [J]. Microbiome, 2017, 5(1): 153.
[15]
Allert S, Foerster TM, Svensson CM, et al. Candida albicans-induced epithelial damage mediates translocation through intestinal barriers [J]. mBio, 2018, 9(3): e00915-e00918.
[16]
Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract [J]. Virulence, 2017, 8(3): 352-358.
[17]
Valenza G, Tuschak C, Nickel S, et al. Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community [J]. Infect Dis (Lond), 2015, 47(9): 654-657.
[18]
Okuda J, Hayashi N, Okamoto M, et al. Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na，K-ATPase regulator, FXYD3 [J]. Infect Immun, 2010, 78(11): 4511-4522.
[19]
Deitch EA. Role of bacterial translocation in necrotizing enterocolitis [J]. Acta Paediatr Suppl, 1994, 396: 33-36.
[20]
Azam MW, Khan AU. Updates on the pathogenicity status of Pseudomonas aeruginosa [J]. Drug Discov Today, 2019, 24(1): 350-359.
[21]
Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of enterococci [J]. Microbiol Spectr, 2019, 7(4): 10.
[22]
Krediet RT, Struijk DG. Peritoneal changes in patients on long-term peritoneal dialysis [J]. Nat Rev Nephrol, 2013, 9(7): 419-429.
[23]
赵晶，杨立明，朱学研，等. 长腹膜透析龄患者首次腹膜炎的临床特征及治疗转归：基于4家医院625例患者数据[J]. 南方医科大学学报，2020, 40(12): 1740-1746.
[24]
Wang X, Han Q, Wang T, et al. Serum albumin changes and mortality risk of peritoneal dialysis patients [J]. Int Urol Nephrol, 2020, 52(3): 565-571.
[1]
Tang SCW, Lai KN. Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant [J]. J Nephrol, 2020, 33(6): 1189-1194.
[2]
Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis [J]. Nat Rev Nephrol, 2017, 13(2): 90-103.
[3]
Scarpioni R, Manini A, Chiappini P. Remote patient monitoring in peritoneal dialysis helps reduce risk of hospitalization during Covid-19 pandemic [J]. J Nephrol, 2020, 33(6): 1123-1124.
[4]
Szeto CC, Li PK. Peritoneal dialysis-associated peritonitis [J]. Clin J Am Soc Nephrol, 2019, 14(7): 1100-1105.
[5]
Lin WH, Tseng CC, Wu AB, et al. Clinical and microbiological characteristics of peritoneal dialysis-related peritonitis caused by Escherichia coli in southern Taiwan [J]. Eur J Clin Microbiol Infect Dis, 2018, 37(9): 1699-1707.
[6]
Lin WH, Tseng CC, Wu AB, et al. Clinical and microbiological characteristics of peritoneal dialysis-related peritonitis caused by Klebsiella pneumoniae in southern Taiwan [J]. J Microbiol Immunol Infect, 2015, 48(3): 276-283.
[7]
许戎，胡宁，阿荣其其格，等. 肠源性与非肠源性腹膜透析相关性腹膜炎的临床特点及预后[J]. 中国血液净化，2012, 11(11): 621-625.
[25]
Uddin F, Imam SH, Khan S, et al. NDM production as a dominant feature in carbapenem-resistant Enterobacteriaceae isolates from a tertiary care hospital [J]. Antibiotics (Basel), 2021, 11(1): 48.
[26]
Szeto CC, Chow KM, Leung CB, et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases [J]. Kidney Int, 2001, 59(6): 2309-2315.
[27]
Siva B, Hawley CM, Mcdonald SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases [J]. Clin J Am Soc Nephrol, 2009, 4(5): 957-964.
[28]
Olivares E, Badel-Berchoux S, Provot C, et al. Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections [J]. Front Microbiol, 2019, 10: 2894.
[29]
李忻阳，张禹，罗佩婷，等. 腹膜透析相关性真菌性腹膜炎的防治进展[J/CD]. 中华肾病研究电子杂志，2020, 9(6): 260-263.
[30]
Pereira R, Dos Santos Fontenelle RO, de Brito EHS, et al. Biofilm of Candida albicans: formation, regulation and resistance [J]. J Appl Microbiol, 2021, 131(1): 11-22.
[31]
刘美君，杨立明，朱学研，等. 腹膜透析相关的混合菌感染的发生和治疗失败的危险因素——814例多中心回顾性研究[J]. 南方医科大学学报，2021, 41(9): 1350-1357.
[1] 明昊, 肖迎聪, 巨艳, 宋宏萍. 乳腺癌风险预测模型的研究现状[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 287-291.
[2] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[3] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[4] 罗文斌, 韩玮. 胰腺癌患者首次化疗后中重度骨髓抑制的相关危险因素分析及预测模型构建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 357-362.
[5] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[6] 林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[7] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[8] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[9] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[10] 王涛, 刘静, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗生素耐药背景下中医药防治腹膜透析相关性腹膜炎研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 340-344.
[11] 司楠, 孙洪涛. 创伤性脑损伤后肾功能障碍危险因素的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 300-305.
[12] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
[13] 李文哲, 王毅, 崔建, 郑启航, 王靖彦, 于湘友. 新疆维吾尔自治区重症患者急性肾功能异常的危险因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 269-276.
[14] 刘志超, 胡风云, 温春丽. 山西省脑卒中危险因素与地域的相关性分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 424-433.
[15] 曹亚丽, 高雨萌, 张英谦, 李博, 杜军保, 金红芳. 儿童坐位不耐受的临床进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 510-515.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？